-

AbCellera to Present at Upcoming Investor Conferences in November

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following investor conferences:

  • Credit Suisse 31st Annual Healthcare Conference on Wednesday, November 9, 2022, at 3:50 p.m. Pacific Time (6:50 p.m. Eastern Time)
  • Stifel 2022 Healthcare Conference on Tuesday, November 15, 2022, at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time)

Live audio webcasts of each presentation may be accessed through links that will be posted on AbCellera's Investor Relations website. Replays of each webcast will be available through the same links following the presentations.

About AbCellera Biologics Inc.
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.

Source: AbCellera Biologics Inc.

Contacts

Inquiries
Media: Jessica Yingling, Ph.D.; media@abcellera.com, +1(236)521-6774
Business Development: Murray McCutcheon, Ph.D.; bd@abcellera.com, +1(604)559-9005
Investor Relations: Josephine Hellschlienger, Ph.D.; ir@abcellera.com, +1(778)729-9116

AbCellera Biologics Inc.

NASDAQ:ABCL

Release Summary
AbCellera to Present at Upcoming Investor Conferences in November
Release Versions
$Cashtags

Contacts

Inquiries
Media: Jessica Yingling, Ph.D.; media@abcellera.com, +1(236)521-6774
Business Development: Murray McCutcheon, Ph.D.; bd@abcellera.com, +1(604)559-9005
Investor Relations: Josephine Hellschlienger, Ph.D.; ir@abcellera.com, +1(778)729-9116

Social Media Profiles
More News From AbCellera Biologics Inc.

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635...

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera to Present at Upcoming Investor Conferences in May and June 2026...

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call...
Back to Newsroom